Clinical Trials for Depression
510 depression trials indexed, 210 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Depression
Depression is a common mental health disorder characterized by persistent feelings of sadness, loss of interest, and a range of emotional and physical problems. It involves changes in brain chemistry and function, particularly in areas that regulate mood, motivation, and stress response. Scientists believe that imbalances in neurotransmitters such as serotonin, norepinephrine, and dopamine contribute to the condition. Diagnosis typically involves a clinical evaluation by a healthcare professional using criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). This evaluation includes assessing the duration and severity of symptoms and ruling out other medical or psychiatric causes.
Common symptoms of depression include a depressed mood most of the day, diminished interest or pleasure in activities, changes in appetite or weight, sleep disturbances, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and thoughts of death or suicide. Depression can begin at any age but often starts in late adolescence or early adulthood. Women are about twice as likely as men to experience depression, and risk factors include a family history of depression, stressful life events, chronic illness, and substance abuse. Social isolation and economic hardship also increase vulnerability.
Depression is a major public health concern because it affects an estimated 5% of adults worldwide at any given time. It is a leading cause of disability and contributes significantly to the global burden of disease. The World Health Organization reports that depression is responsible for more than 50 million years lived with disability globally. Beyond personal suffering, depression affects social relationships, work productivity, and overall quality of life. It also increases the risk of suicide, which accounts for nearly 800,000 deaths annually worldwide.
The Depression Treatment Landscape
The first-line treatment for depression usually involves antidepressant medications combined with psychotherapy. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed drugs due to their relatively favorable side effect profile. Examples include fluoxetine and sertraline. Cognitive-behavioral therapy (CBT) is a widely used form of talk therapy that helps patients change negative thought patterns. Treatment often begins with one antidepressant, and doctors monitor the patient’s response over several weeks. If symptoms improve, medication may continue for several months to prevent relapse.
For patients who do not respond to initial treatment, second-line options include switching to a different antidepressant or adding another medication. Other classes of antidepressants used include serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine, tricyclic antidepressants, and atypical antidepressants such as bupropion. Third-line treatments may involve augmentation strategies with mood stabilizers or antipsychotic drugs. Electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are considered for severe or treatment-resistant cases.
Despite the availability of multiple treatments, many patients experience incomplete relief or significant side effects. About 30% of people with depression do not respond adequately to standard therapies, a condition known as treatment-resistant depression. Common side effects include weight gain, sexual dysfunction, and fatigue, which can reduce adherence. Research is focused on developing new medications that target different biological pathways and improving non-drug interventions. Efforts also aim to identify patient subgroups for more personalized treatment approaches.
Why Clinical Trials Matter for Depression
Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial can provide closer monitoring by healthcare professionals and contribute valuable information to the understanding of depression. According to ClinicalTrials.gov, there are currently 510 depression clinical trials indexed, with 210 actively recruiting participants. These trials investigate a range of interventions, including novel medications, psychotherapy techniques, and brain stimulation methods. Volunteers play an essential role in advancing medical knowledge and improving future care options.
Joining a clinical trial also involves certain risks. New treatments may not be effective or could cause unexpected side effects. Some trials include a placebo group, meaning participants might receive a non-active treatment instead of the experimental one. Additional clinic visits and tests can require more time and effort. It is important for potential participants to discuss the possible benefits and risks with their healthcare provider before enrolling.
The sponsors of depression clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. These organizations design and fund studies to test new therapies and improve existing ones. ClinicalTrials.gov serves as a public registry that provides information about ongoing and completed trials, helping patients and clinicians find relevant studies. This transparency supports informed decision-making and encourages collaboration across the research community.
What to Look for in a Depression Clinical Trial
Clinical trials are conducted in phases that help researchers understand the safety and effectiveness of new treatments. Phase 1 trials focus on safety and dosage, usually involving a small number of participants. Phase 2 trials test the treatment’s effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to current standard treatments in even larger groups. Phase 4 trials occur after approval to monitor long-term effects. For depression trials, the distribution is different: 317 trials have no phase specified, 63 are in Phase 2, 26 in Phase 1, and 24 in Phase 3. Phase 2 is the most common phase among those with a specified stage.
When considering a depression clinical trial, inclusion criteria are important to know. These criteria often specify age ranges, such as adults 18 to 65 years old. Some trials require participants to have tried certain antidepressant medications before joining. Biomarkers or specific clinical assessments may also be used to confirm depression diagnosis or severity. The duration of the depressive episode and how long the person has had symptoms might also be factors. These criteria help ensure that the study group is appropriate for the treatment being tested.
Exclusion criteria are just as important. They prevent people with certain conditions from joining for safety reasons or to avoid interfering with results. For example, people with other mental health disorders like bipolar disorder or schizophrenia may be excluded. Those taking medications that could interact with the study drug might also be excluded. Some trials exclude participants with serious medical problems such as heart disease or liver issues. These rules help protect participants and keep the study focused on depression.
Practical considerations matter when deciding to join a trial. The length of the trial can vary from a few weeks to several months. Visit schedules might require frequent trips to the clinic, which can be challenging for some people. Travel distance and costs should be considered before enrolling. It is helpful to ask the research team questions such as: How often will I need to come to the clinic? What side effects should I expect? Will I be able to continue my current treatments? What support is available if I experience worsening symptoms? Knowing these details helps participants make informed decisions.
Primary Sources and Further Reading
For those interested in learning more about depression and clinical trials, several reliable sources provide detailed information. These resources cover symptoms, treatments, research updates, and how to find clinical trials. They are maintained by respected health organizations and government agencies. Exploring these sites can help patients and caregivers better understand depression and available research options.
- National Institute of Mental Health: Depression
- MedlinePlus: Depression
- ClinicalTrials.gov: Depression Studies
- National Institutes of Health: Depression
- Centers for Disease Control and Prevention: Mental Health
Latest Research and Emerging Treatments for Depression (2026)
Recent depression research includes several Phase 3 trials testing new drugs and therapies for major depressive disorder. One study is evaluating MM120, an oral medication based on LSD D-Tartrate, which may work by affecting brain receptors involved in mood regulation (NCT06941844). This trial compares MM120 to a placebo over 12 weeks to assess safety and effectiveness. If successful, MM120 could provide a new option for people living with depression who need alternatives to current treatments.
Another promising approach is the use of solriamfetol, a drug being tested for adults with depression who experience excessive daytime sleepiness (NCT07484217). Solriamfetol acts on brain chemicals that regulate wakefulness and alertness. Managing daytime sleepiness could improve daily functioning and quality of life for those whose depression symptoms include fatigue and difficulty staying awake. This trial is exploring whether solriamfetol can safely reduce sleepiness while also supporting mood improvement.
For treatment-resistant depression, ketamine combined with virtual reality therapy is under study in Canada (NCT06781697). Ketamine is known to affect glutamate, a brain chemical linked to mood and cognition, and may provide faster relief than traditional antidepressants. Adding virtual reality aims to enhance the therapeutic experience and possibly improve outcomes. Similarly, psilocybin-assisted therapy is being tested in the United States for people whose depression has not responded to other treatments (NCT06303739). Psilocybin, a compound found in certain mushrooms, may help reset brain activity patterns associated with depression. These new drugs for depression and therapy combinations could offer more options for patients who have struggled with existing treatments.
Frequently asked questions about Depression trials
How do I find Depression clinical trials?
The authoritative source for Depression clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 510 depression studies are currently indexed. You can search by entering "depression" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new depression trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Depression trials in?
Across the 510 depression trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Depression clinical trials are currently recruiting?
As of the latest scan, 210 depression trials have a "Recruiting" status on ClinicalTrials.gov, out of 510 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting depression trial matches their tracked condition.
Stay informed about depression research
Get a weekly briefing with the trials that matter most.